EGI
NRIX icon

EAM Global Investors’s Nurix Therapeutics NRIX Stock Holding History

EAM Global Investors’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-50,353
Closed -$1.76M – 163
2020
Q3 		$1.76M Buy
+50,353
New +$1.27M 0.64% 73

Other funds holding NRIX

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM Global Investors's NRIX Position: Q4 2020 in Review

EAM Global Investors sold out of Nurix Therapeutics (NRIX) in Q4 2020, closing a stake of 50,353 shares — an estimated $1.76M sold.

EAM Global Investors first reported a position in NRIX in Q3 2020 and held it in 1 quarter. The position peaked at $1.76M in Q3 2020. 68 funds tracked by Wall St. Rank hold NRIX as of Q4 2020.

  • EAM Global Investors reported no remaining Nurix Therapeutics position as of Q4 2020 after selling out during the quarter.
  • EAM Global Investors sold 50,353 Nurix Therapeutics shares in Q4 2020, an estimated $1.76M.
  • EAM Global Investors first reported a position in Nurix Therapeutics in Q3 2020 and held it in 1 quarter.
  • EAM Global Investors's Nurix Therapeutics position peaked at $1.76M in Q3 2020.
  • 68 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q4 2020.

Based on EAM Global Investors's 13F filing for Q4 2020, filed 11 Feb 2021.